PMID- 33402588
OWN - NLM
STAT- MEDLINE
DCOM- 20211129
LR  - 20220423
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 58
IP  - 2
DP  - 2021 Apr-Jun
TI  - The efficacy and safety of onartuzumab in patients with solid cancers: A 
      meta-analysis of randomized trials.
PG  - 232-240
LID - 10.4103/ijc.IJC_797_18 [doi]
AB  - BACKGROUND: Onartuzumab, a humanized monovalent monoclonal antibody to the MET 
      protein, has been tested in various cancers. We conducted a meta-analysis of 
      randomized phase II and III clinical trials to investigate the efficacy and 
      safety of onartuzumab in solid cancers. METHODS: We searched PubMed, PMC, EMBASE, 
      and the Cochrane library databases. We included randomized phase II or III trials 
      that evaluated the additional benefits of onartuzumab in comparison with the 
      standard treatments. Data on progression-free survival (PFS), overall survival 
      (OS), and adverse events (AEs) were pooled and analyzed. RESULTS: From nine 
      studies, a total of 2,138 patients were included in the meta-analysis. The 
      addition of onartuzumab to the standard treatment resulted in no improvement of 
      PFS (hazard ratio (HR) = 1.00 [95% confidence interval (CI), 0.90-1.11], P = 
      0.93) and OS (HR = 1.08 [95% CI, 0.94-1.23], P = 0.29). In the subgroup analysis 
      with patients with non-small-cell lung cancer (NSCLC), onartuzumab was not 
      associated with a significant improvement of OS (HR = 1.12 [95% CI, 0.93-1.34], P 
      = 0.23) and PFS (HR = 1.05 [95% CI, 0.91-1.21], P = 0.52). With respect to AEs, 
      onartuzumab increased the incidence of hypoalbuminemia (odds ratio (OR) = 14.8 
      [95% CI, 3.49-62.71], P < 0.001), peripheral edema (OR = 6.52 [95% CI, 
      3.60-11.81], P < 0.001), neutropenia (OR = 1.36 [95% CI, 1.03-1.79], P = 0.03), 
      thrombocytopenia (OR = 1.98 [95% CI, 1.03-3.81], P = 0.04), and venous thrombotic 
      events (OR = 3.05 [95% CI, 1.39-6.71], P = 0.006). CONCLUSION: This meta-analysis 
      indicates that the addition of onartuzumab to the standard treatments had no 
      definite survival benefit with increased severe toxicities in patients with solid 
      cancer.
FAU - Kim, Bum Jun
AU  - Kim BJ
AD  - Department of Internal Medicine, Hallym University Medical Center, Hallym 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Kim, Dalyong
AU  - Kim D
AD  - Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, 
      Republic of Korea.
FAU - Kim, Jung Han
AU  - Kim JH
AD  - Department of Internal Medicine, Hallym University Medical Center, Hallym 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Kim, Hyeong Su
AU  - Kim HS
AD  - Department of Internal Medicine, Hallym University Medical Center, Hallym 
      University College of Medicine, Seoul, Republic of Korea.
FAU - Jang, Hyun Joo
AU  - Jang HJ
AD  - Department of Internal Medicine, Hallym University Medical Center, Hallym 
      University College of Medicine, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 2.7.10.1 (MET protein, human)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - MS1J9720WC (onartuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy/pathology
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-met/*antagonists & inhibitors/immunology
MH  - Randomized Controlled Trials as Topic/*statistics & numerical data
MH  - Survival Rate
OTO - NOTNLM
OT  - Anti-MET inhibitor
OT  - meta-analysis
OT  - onartuzumab
OT  - review
COIS- None
EDAT- 2021/01/07 06:00
MHDA- 2021/11/30 06:00
CRDT- 2021/01/06 05:39
PHST- 2021/01/07 06:00 [pubmed]
PHST- 2021/11/30 06:00 [medline]
PHST- 2021/01/06 05:39 [entrez]
AID - 299724 [pii]
AID - 10.4103/ijc.IJC_797_18 [doi]
PST - ppublish
SO  - Indian J Cancer. 2021 Apr-Jun;58(2):232-240. doi: 10.4103/ijc.IJC_797_18.